西地那非对慢性心力衰竭并发肺动脉高压的临床效果
|
摘要
目的探讨西地那非临床对慢性心力衰竭并发肺动脉高压的临床效果。方法选取2017年7月至2018年8月山东聊城高唐县人民医院收治的慢性心力衰竭并发肺动脉高压患者86例开展研究,按照双盲数字随机法分成两组,每组43例。对照组行基础治疗,研究组在对照组治疗的基础上应用西地那非,治疗前后心功能各项指标左室射血分数(LVEF),左室短轴缩短率(LVFS),6分钟步行距离(6MTW);血管内皮生长因子(VEGF),内皮素-1(ET-1),一氧化氮(NO)。结果比较治疗后研究组和对照组心功能各项指标,6MTW指标明显优于对照组,差异有统计学意义(P <0.05)。治疗后,ET-1、VEGF、NO指标较治疗前均有改善,组间比较差异均有统计学意义(P <0.05)。两组均未发生严重不良反应,比较无明显差异,P> 0.05。结论西地那非临床对慢性心力衰竭并发肺动脉高压疗效分析效果显著,且药物使用安全性较好,无严重不良反应。
Objective To investigate the clinical effect of Sildenafil on chronic heart failure with pulmonary hypertension. Methods 86 patients with chronic heart failure with pulmonary hypertension were selected from July 2017 to August 2018 by Gaotang County People's Hospital. In the control group, the control group used Sildenafil on the basis of treatment, and the left ventricular ejection fraction(LVEF), left ventricular short-axis shortening rate(LVFS), 6-minute walking distance(6 MTW)were used in the control group. Vascular endothelial growth factor.(VEGF), Endothelin-1(ET-1),nitric oxide(NO). Results After treatment, the indexes of cardiac function in the study group and the control group were significantly better than those in the control group, and the difference was statistically significant(P < 0.05).After treatment, the ET-1,VEGF,NO index was improved compared with that before treatment, and the difference between the two groups was statistically significant(P < 0.05). There was no serious adverse reaction between the two groups,and there was no significant difference between the two groups(P > 0.05). Conclusion: sildenafil is effective in the treatment of chronic heart failure complicated with pulmonary hypertension, and the drug is safe and has no serious adverse reactions.
Objective To investigate the clinical effect of Sildenafil on chronic heart failure with pulmonary hypertension. Methods 86 patients with chronic heart failure with pulmonary hypertension were selected from July 2017 to August 2018 by Gaotang County People's Hospital. In the control group, the control group used Sildenafil on the basis of treatment, and the left ventricular ejection fraction(LVEF), left ventricular short-axis shortening rate(LVFS), 6-minute walking distance(6 MTW)were used in the control group. Vascular endothelial growth factor.(VEGF), Endothelin-1(ET-1),nitric oxide(NO). Results After treatment, the indexes of cardiac function in the study group and the control group were significantly better than those in the control group, and the difference was statistically significant(P < 0.05).After treatment, the ET-1,VEGF,NO index was improved compared with that before treatment, and the difference between the two groups was statistically significant(P < 0.05). There was no serious adverse reaction between the two groups,and there was no significant difference between the two groups(P > 0.05). Conclusion: sildenafil is effective in the treatment of chronic heart failure complicated with pulmonary hypertension, and the drug is safe and has no serious adverse reactions.
引文
[1]陈志丹.不同方法治疗慢性心力衰竭的临床效果比较分析[J].中华医学杂志,2014,21(2):851-853.
[2]何建国.口服西地那非治疗慢性心力衰竭肺动脉高压的临床效果观察[J].上海实用心血管杂志,2012,199(8):746-748.
[3]李尚月.左心衰竭伴肺动脉高压的临床药物治疗效果分析[J].国家心力衰竭研究协会,2015,18(1):867-869.
[4]诸葛瑞琪,倪新海.左心疾病相关性肺动脉高压和药物治疗进展[J].中国心血管杂志,2016,12(2):231-232.
[5]杨京华,朱晨曦,王增智,等.贝前列素钠联合西地那非治疗肺动脉高压的临床观察[J].心肺血管病杂志,2014,42(6):622-623.
[6]闫芳,夏宇,李威,等.西地那非治疗肺动脉高压的疗效及安全性研究[J].中国临床药理学杂志,2014,25(10):1253-1254.
[7]王全政,秦毅,沃金善.血浆NT-proBNP水平及肺动脉收缩压对慢性左心心力衰竭病人预后的预测价值[J].齐鲁医学杂志,2014,23(5):599-601.
[8]赵施皓,杨智伟,郑墟旸,等.microRNA在肺动脉高压形成中的作用[J].心脏杂志,2013,25(4):494-498.
[9]闫芳,夏宇,李威,等.西地那非治疗肺动脉高压的疗效及安全性研究[J].中国临床药理学杂志,2014,30(10):877-879.
[10]Correale M,Totaro A,Ferraretti A,et al.Sildenafil improves clinical and functional status of an elderly postmenopausal female with'out of proportion'PH associated with left heart disease[J].Monaldi Arch Chest Dis,2013,80(4):193-194.
[11]张健,张宇辉.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,36(2):254-256.
[12]殷晓明,胡晓荃,张金惠,等.老年慢性阻塞性肺病稳定期血浆前白蛋白、脑钠肽及C反应蛋白水平与肺动脉高压的相关性[J].中国老年学杂志,2013,56(20):6987-6988.
[13]赵施皓,杨智伟,郑煦暘,等.microRNA在肺动脉高压形成中的作用[J].心脏杂志,2013,23(4):499-500.
[2]何建国.口服西地那非治疗慢性心力衰竭肺动脉高压的临床效果观察[J].上海实用心血管杂志,2012,199(8):746-748.
[3]李尚月.左心衰竭伴肺动脉高压的临床药物治疗效果分析[J].国家心力衰竭研究协会,2015,18(1):867-869.
[4]诸葛瑞琪,倪新海.左心疾病相关性肺动脉高压和药物治疗进展[J].中国心血管杂志,2016,12(2):231-232.
[5]杨京华,朱晨曦,王增智,等.贝前列素钠联合西地那非治疗肺动脉高压的临床观察[J].心肺血管病杂志,2014,42(6):622-623.
[6]闫芳,夏宇,李威,等.西地那非治疗肺动脉高压的疗效及安全性研究[J].中国临床药理学杂志,2014,25(10):1253-1254.
[7]王全政,秦毅,沃金善.血浆NT-proBNP水平及肺动脉收缩压对慢性左心心力衰竭病人预后的预测价值[J].齐鲁医学杂志,2014,23(5):599-601.
[8]赵施皓,杨智伟,郑墟旸,等.microRNA在肺动脉高压形成中的作用[J].心脏杂志,2013,25(4):494-498.
[9]闫芳,夏宇,李威,等.西地那非治疗肺动脉高压的疗效及安全性研究[J].中国临床药理学杂志,2014,30(10):877-879.
[10]Correale M,Totaro A,Ferraretti A,et al.Sildenafil improves clinical and functional status of an elderly postmenopausal female with'out of proportion'PH associated with left heart disease[J].Monaldi Arch Chest Dis,2013,80(4):193-194.
[11]张健,张宇辉.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,36(2):254-256.
[12]殷晓明,胡晓荃,张金惠,等.老年慢性阻塞性肺病稳定期血浆前白蛋白、脑钠肽及C反应蛋白水平与肺动脉高压的相关性[J].中国老年学杂志,2013,56(20):6987-6988.
[13]赵施皓,杨智伟,郑煦暘,等.microRNA在肺动脉高压形成中的作用[J].心脏杂志,2013,23(4):499-500.